Profile data is unavailable for this security.
About the company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-53.45m
- Incorporated2021
- Employees42.00
- LocationSurrozen Inc171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 475-2820
- Fax+1 (302) 655-5049
- Websitehttps://www.surrozen.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quince Therapeutics Inc | 0.00 | -53.12m | 33.19m | 32.00 | -- | 0.7067 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Unicycive Therapeutics Inc | 0.00 | -24.41m | 34.17m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
FibroGen Inc | 173.82m | -168.32m | 34.40m | 486.00 | -- | -- | -- | 0.1979 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 34.44m | 4.00 | -- | 9.89 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 35.16m | 73.00 | -- | 1.05 | -- | 14.92 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -31.75m | 35.54m | 17.00 | -- | 2.04 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Protara Therapeutics Inc | 0.00 | -40.69m | 36.31m | 26.00 | -- | 0.3944 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
Surrozen Inc | 0.00 | -53.45m | 36.35m | 42.00 | -- | 6.00 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 36.86m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Passage Bio Inc | 0.00 | -76.57m | 37.12m | 58.00 | -- | 0.4099 | -- | -- | -1.36 | -1.36 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -47.99 | -48.56 | -53.39 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
Singular Genomics Systems Inc | 2.72m | -91.89m | 37.76m | 255.00 | -- | 0.2738 | -- | 13.87 | -37.37 | -37.37 | 1.11 | 55.27 | 0.0108 | 0.2867 | 11.53 | 10,674.51 | -36.46 | -- | -38.85 | -- | -41.11 | -- | -3,375.72 | -- | 8.04 | -- | 0.0696 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
NextCure Inc | 0.00 | -61.28m | 37.77m | 82.00 | -- | 0.442 | -- | -- | -2.20 | -2.20 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -47.88 | -22.59 | -51.64 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Carisma Therapeutics Inc | 20.71m | -72.50m | 39.17m | 107.00 | -- | 108.80 | -- | 1.89 | -1.78 | -1.78 | 0.5075 | 0.0087 | 0.2153 | -- | -- | 193,551.40 | -75.38 | -30.87 | -91.33 | -34.47 | -- | -- | -350.08 | -255.66 | -- | -- | 0.8322 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
DURECT Corp | 8.41m | -15.80m | 39.42m | 47.00 | -- | 7.83 | -- | 4.69 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 40.04m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 10 Apr 2024 | 282.58k | 8.83% |
Armistice Capital LLCas of 10 Apr 2024 | 190.00k | 5.94% |
Goldman Sachs & Co. LLC (Private Banking)as of 10 Apr 2024 | 172.67k | 5.40% |
Euclidean Capital LLCas of 31 Mar 2024 | 87.70k | 2.74% |
Nantahala Capital Management LLCas of 10 Apr 2024 | 74.19k | 2.32% |
Heights Capital Management, Inc.as of 10 Apr 2024 | 64.91k | 2.03% |
StemPoint Capital LPas of 10 Apr 2024 | 64.50k | 2.02% |
Stonepine Capital Management LLCas of 10 Apr 2024 | 64.50k | 2.02% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 61.08k | 1.91% |
ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 55.12k | 1.72% |